{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T00:28:53Z","timestamp":1774744133609,"version":"3.50.1"},"reference-count":35,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2017,7,10]],"date-time":"2017-07-10T00:00:00Z","timestamp":1499644800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004339","name":"sanofi-aventis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Bristol-Myers Squibb"},{"name":"Waksman Foundation"},{"name":"World Heart Federation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Cardiology"],"published-print":{"date-parts":[[2017,10]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>It remains uncertain whether patients with atrial fibrillation (<jats:styled-content style=\"fixed-case\">AF<\/jats:styled-content>) requiring long\u2010term oral anticoagulation (<jats:styled-content style=\"fixed-case\">OAC<\/jats:styled-content>) and with stable coronary artery disease (<jats:styled-content style=\"fixed-case\">CAD<\/jats:styled-content>) should receive antiplatelet therapy (<jats:styled-content style=\"fixed-case\">APT<\/jats:styled-content>) in addition to <jats:styled-content style=\"fixed-case\">OAC<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Hypothesis<\/jats:title><jats:p>APT in addition to OAC would be more effective than OAC alone in preventing ischaemic events in such patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In the international REduction of Atherothrombosis for Continued Health (REACH) Registry including 68 236 outpatients with or at risk for atherothrombosis, we identified 2347 patients with stable CAD and AF receiving vitamin K antagonists (VKA). Using propensity score matching, patients treated with <jats:styled-content style=\"fixed-case\">VKA<\/jats:styled-content> (n = 1481) were compared with those receiving <jats:styled-content style=\"fixed-case\">VKA<\/jats:styled-content> + <jats:styled-content style=\"fixed-case\">APT<\/jats:styled-content> at inclusion (n = 866). The primary outcome was major adverse cardiovascular events (<jats:styled-content style=\"fixed-case\">MACE<\/jats:styled-content>) at 4 years (cardiovascular death, myocardial infarction, or stroke). Secondary outcomes were all\u2010cause death and bleeding leading to hospitalization and transfusion.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Patients receiving <jats:styled-content style=\"fixed-case\">VKA<\/jats:styled-content> only were older (74 vs 72 years, <jats:italic>P<\/jats:italic> &lt; 0.01), had less diabetes (37% vs 42%, <jats:italic>P<\/jats:italic> = 0.02), and less frequent history of percutaneous coronary intervention (28.7% vs 43.9%, <jats:italic>P<\/jats:italic> &lt; 0.01). The mean <jats:styled-content style=\"fixed-case\">CHA<jats:sub>2<\/jats:sub>DS<jats:sub>2<\/jats:sub>\u2010VaSc<\/jats:styled-content> score was 4.9 in the <jats:styled-content style=\"fixed-case\">VKA<\/jats:styled-content> group vs 4.7 in the <jats:styled-content style=\"fixed-case\">VKA<\/jats:styled-content> + <jats:styled-content style=\"fixed-case\">APT<\/jats:styled-content> group (<jats:italic>P<\/jats:italic> &lt; 0.01). After propensity score matching, the rate of <jats:styled-content style=\"fixed-case\">MACE<\/jats:styled-content> was similar between groups: hazard ratio = 1.01 (0.77\u20101.33) (<jats:italic>P<\/jats:italic> = 0.94), whereas bleeding tended to be more frequent in the <jats:styled-content style=\"fixed-case\">VKA<\/jats:styled-content> + <jats:styled-content style=\"fixed-case\">APT<\/jats:styled-content> group: odds ratio = 1.87 (0.99\u20103.50) (<jats:italic>P<\/jats:italic> = 0.051).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In this observational analysis, the use of <jats:styled-content style=\"fixed-case\">APT<\/jats:styled-content> in addition to <jats:styled-content style=\"fixed-case\">OAC<\/jats:styled-content> in patients with stable <jats:styled-content style=\"fixed-case\">CAD<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">AF<\/jats:styled-content> was not associated with lower risk of ischemic events but possibly with higher bleeding rates. Randomized trials are necessary to determine the optimal long\u2010term antithrombotic strategy.<\/jats:p><\/jats:sec>","DOI":"10.1002\/clc.22750","type":"journal-article","created":{"date-parts":[[2017,7,10]],"date-time":"2017-07-10T16:13:43Z","timestamp":1499703223000},"page":"932-939","source":"Crossref","is-referenced-by-count":49,"title":["Vitamin K antagonists with or without long\u2010term antiplatelet therapy in outpatients with stable coronary artery disease and atrial fibrillation: Association with ischemic and bleeding events"],"prefix":"10.1002","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2917-9273","authenticated-orcid":false,"given":"Gilles","family":"Lemesle","sequence":"first","affiliation":[{"name":"Pasteur Institute of Lille, INSERM UMR 1011, Lille, France; School of Medicine and University of Lille, Lille, France; Cardiology Department Regional and Universitary Hospital of Lille  Lille France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4069-1128","authenticated-orcid":false,"given":"Gregory","family":"Ducrocq","sequence":"additional","affiliation":[{"name":"Universitary and Hospital Department of FIRE (Fibrosis, Inflammation, Remodeling), University of Paris\u2010Diderot, Sorbonne Paris Cit\u00e9, Paris France; FACT (French Alliance for Cardiovascular Trials); Hospital of Bichat, Public Assistance of Hospital of Paris, Paris, France; INSERM U\u20101148  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yedid","family":"Elbez","sequence":"additional","affiliation":[{"name":"Universitary and Hospital Department of FIRE (Fibrosis, Inflammation, Remodeling), University of Paris\u2010Diderot, Sorbonne Paris Cit\u00e9, Paris France; FACT (French Alliance for Cardiovascular Trials); Hospital of Bichat, Public Assistance of Hospital of Paris, Paris, France; INSERM U\u20101148  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Van Belle","sequence":"additional","affiliation":[{"name":"Pasteur Institute of Lille, EGID, INSERM UMR 1011, Lille, France; School of Medicine and University of Lille, Lille, France; Cardiology Department, Regional and Universitary Hospital of Lille  Lille France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Goto","sequence":"additional","affiliation":[{"name":"Department of Medicine (Cardiology) and Research Center for Metabolic Disease Center, Tokai University School of Medicine Tokai University  Kanagawa Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher P.","family":"Cannon","sequence":"additional","affiliation":[{"name":"Harvard Clinical Research Institute, Cardiovascular Division Brigham and Women's Hospital and Harvard Medical School  Boston Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Bauters","sequence":"additional","affiliation":[{"name":"Pasteur Institute of Lille, INSERM UMR 1167, Lille, France; School of Medicine and University of Lille, Lille, France; Cardiology Department, Regional and Universitary Hospital of Lille  Lille France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1278-6245","authenticated-orcid":false,"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Heart and Vascular Center, Brigham and Women's Hospital, and Harvard Medical School  Boston Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe Gabriel","family":"Steg","sequence":"additional","affiliation":[{"name":"Universitary and Hospital Department of FIRE (Fibrosis, Inflammation, Remodeling), University of Paris\u2010Diderot, Sorbonne Paris Cit\u00e9, Paris France; FACT (French Alliance for Cardiovascular Trials); Hospital of Bichat, Public Assistance of Hospital of Paris, Paris, France; INSERM U\u20101148, Paris, France; National Heart and Lung Institute, Royal Brompton Hospital, Imperial College  London United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the REACH Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,7,10]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e318277d6a0"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000040"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.07.957"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2013.11.030"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2008.06.029"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0125164"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs289"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/eut373"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH13-04-0351"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu298"},{"key":"e_1_2_6_12_1","first-page":"271","article-title":"Impact of the adjunction of aspirin on top of oral anticoagulants in stable coronary artery disease outpatients with an indication for anticoagulation","volume":"58","author":"Schurtz G","year":"2016","journal-title":"Panminerva Med."},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH10-05-0332"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/2048872615610868"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw210"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2010.271"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.2.180"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.1322"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehp355"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.297.11.1197"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehq021"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2010.221788"},{"key":"e_1_2_6_23_1","article-title":"Performing a 1:n case\u2013control match on propensity score. Paper presented at","author":"Parsons LS","year":"2004","journal-title":"Twenty\u2010Ninth Annual SAS Users Group International (SUGI) Conference"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2012.05.016"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.324.7329.71"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht445"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107039"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905561"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.115386"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310907"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.002927"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.002587"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.004834"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2016-309832"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2014-305486"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.11.061"}],"container-title":["Clinical Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fclc.22750","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/clc.22750","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T20:18:41Z","timestamp":1695759521000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/clc.22750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,10]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["10.1002\/clc.22750"],"URL":"https:\/\/doi.org\/10.1002\/clc.22750","archive":["Portico"],"relation":{},"ISSN":["0160-9289","1932-8737"],"issn-type":[{"value":"0160-9289","type":"print"},{"value":"1932-8737","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,10]]}}}